GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a ...

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

GSK plc with its development partner iTeos Therapeutics, Inc., has announced that it is ending the development programme for ...

GSK has already moved on from its decision to drop a cancer asset on Tuesday by snagging a late-stage liver disease candidate ...

Teos Therapeutics faces significant setbacks with the discontinuation of their TIGIT program and belrestotug, leaving them ...

Belgian clinical-stage biotech iTeos Therapeutics (Nasdaq: ITOS) saw its shar leap18.6% to $8.20 today, despite posting ...

Despite the unfavorable trial results, iTeos Therapeutics has initiated a strategic review to maximize shareholder value. The company’s CEO, Michel Detheux, Ph.D., expressed disappointment over the ...

GSK said it is axing development of belrestotug and concluding its iTeos collaboration, which began with $625 million upfront ...

The drug was being developed as a potential treatment for various cancers. GSK said it is expanding from its current focus on blood and women's cancers into lung and gastrointestinal cancers, as well ...